Edgewise Therapeutics, Inc.(EWTX)

$44.62—Stale · unknown old

Ask SA Chart

Edgewise Therapeutics, Inc.(EWTX)

NASDAQ • Last print unknown ago

$44.62—Stale · unknown old

Ask SA Chart Studio

EWTX(EWTX)

EWTX

Q4 2026 EPS Estimate

$-0.55

Nov 5, 2026 · Reports before open

Revenue Estimate

$129M

Analyst Sentiment

Wall St. Consensus

Buy

10 analysts·Moderate coverage

Score

9 Buy (90%)1 Hold (10%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

990%

Hold

110%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$36.00

-19.3%

Consensus

$52.00

+16.5%

Bull

$66.00

+47.9%

12-Month Target Range10 analysts

$36.00$52.00$66.00

Current $44.62Consensus

Current Price

$44.62

Upside to Consensus

$7.38

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+1600.40%

EPS—

FY2028

Rev+132.16%

EPS—

FY2029

Rev+134.94%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$39M	$90M	$211M	$338M
Low	$1M	$17M	$48M	$113M	$181M
High	$4M	$67M	$144M	$339M	$544M
EBITDA Avg	$-213M	$-196M	$-211M	$-131M	$-86M
Low	$-226M	$-235M	$-261M	$-235M	$-154M
High	$-199M	$-43M	$-113M	$-51M	$-33M
EBIT Avg	$-214M	$-197M	$-212M	$-132M	$-86M
Low	$-228M	$-236M	$-262M	$-236M	$-154M
High	$-201M	$-44M	$-114M	$-52M	$-34M
Net Income Avg	$-214M	$-197M	$-212M	$-132M	$-86M
Low	$-228M	$-236M	$-262M	$-236M	$-154M
High	$-201M	$-44M	$-114M	$-52M	$-34M
EPS Avg	$-2.05	$-1.64	$-1.86	$-1.28	$-0.84
Low	$-2.21	$-2.29	$-2.54	$-2.29	$-1.50
High	$-1.96	$-0.43	$-1.11	$-0.51	$-0.33
Analysts (Rev / EPS)	8 / 8	8 / 9	10 / 8	5 / 5	5 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$129M	$10M	—	—	$50M	$6M
Low	$129M	$10M	—	—	$50M	$6M
High	$129M	$10M	—	—	$50M	$6M
EBITDA Avg	$-57M	$-51M	—	—	$-32M	$-22M
Low	$-63M	$-63M	—	—	$-32M	$-22M
High	$-55M	$-40M	—	—	$-32M	$-22M
EBIT Avg	$-57M	$-52M	—	—	$-33M	$-23M
Low	$-64M	$-63M	—	—	$-33M	$-23M
High	$-55M	$-41M	—	—	$-33M	$-23M
Net Income Avg	$-57M	$-52M	$-55M	$-58M	$-33M	$-23M
Low	$-64M	$-63M	$-55M	$-58M	$-33M	$-23M
High	$-55M	$-41M	$-55M	$-58M	$-33M	$-23M
EPS Avg	$-0.53	$-0.48	$-0.51	$-0.54	$-0.30	$-0.21
Low	$-0.59	$-0.59	$-0.51	$-0.54	$-0.30	$-0.21
High	$-0.51	$-0.38	$-0.51	$-0.54	$-0.30	$-0.21
Analysts (Rev / EPS)	12 / 7	12 / 9	— / 6	— / 3	6 / 3	6 / 6

Earnings Surprises

Recent Analyst Actions

Aug 11, 2026Goldman Sachs

Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs

Target:$36.00

-19.2%from $44.58

Jul 20, 2026Evercore ISI

Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI

Target:$55.00

+39.4%from $39.46

Jul 9, 2026Oppenheimer

Edgewise Therapeutics initiated with an Outperform at Oppenheimer

Target:$51.00

+10.2%from $46.30

Jul 6, 2026Guggenheim

Edgewise Therapeutics price target raised to $51 from $41 at Guggenheim

Target:$51.00

+28.0%from $39.83

Jun 17, 2026RBC Capital

Edgewise Therapeutics price target raised to $59 from $48 at RBC Capital

Target:$59.00

+71.0%from $34.51

Jun 17, 2026Goldman Sachs

Edgewise Therapeutics (EWTX) PT Raised to $32 at Goldman Sachs

Target:$32.00

-5.7%from $33.95

Jun 16, 2026Leerink Partners

Edgewise Therapeutics price target raised to $52 from $50 at Leerink

Target:$52.00

+56.3%from $33.28

Jun 2, 2026H.C. Wainwright

Edgewise Therapeutics price target raised to $45 from $42 at H.C. Wainwright

Target:$45.00

+19.8%from $37.57

Jun 2, 2026RBC Capital

Edgewise Therapeutics (EWTX) PT Lowered to $48 at RBC Capital

Target:$48.00

+25.4%from $38.27

Jun 1, 2026Raymond James

Edgewise Therapeutics price target raised to $66 from $52 at Raymond James

Target:$66.00

+63.9%from $40.26

Jun 1, 2026Wedbush

Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush

Target:$52.00

+29.2%from $40.26

May 6, 2026Truist Financial

Edgewise Therapeutics price target raised to $52 from $46 at Truist

Target:$52.00

+39.4%from $37.30

Mar 10, 2026Raymond James

Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow"

Target:$46.00

+55.0%from $29.67

Feb 26, 2026Evercore ISI

Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI

Target:$45.00

+51.7%from $29.66

Feb 26, 2026Stifel Nicolaus

Edgewise Therapeutics (EWTX) PT Raised to $25 at Stifel

Target:$25.00

-16.2%from $29.83

Sep 24, 2025Goldman Sachs

Goldman Sachs assigns Neutral rating to Edgewise Therapeutics

Target:$20.00

+20.6%from $16.59

Mar 7, 2025Scotiabank

Edgewise Therapeutics initiated with an Outperform at Scotiabank

Target:$50.00

+78.5%from $28.01

Dec 5, 2024Truist Financial

Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'

Target:$50.00

+58.4%from $31.57

Oct 11, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

Target:$51.00

+67.5%from $30.45

Sep 20, 2024RBC Capital

Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital

Target:$42.00

+42.4%from $29.50

Sep 19, 2024Leerink Partners

Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners

Target:$42.00

+42.4%from $29.50

Jul 1, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)

Target:$48.00

+166.5%from $18.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance